MELBOURNE, August 23, 2026, 08:10 AEST
- CSL finished Friday at A$168.30, marking a 23.3% gain over the week.
- The surge pushed CSL past the average analyst target of A$163.62.
- FY27 outlook forecasts approximately 5% profit increase alongside a 25% drop in Vifor revenue.
CSL Limited ASX:CSL finished its strongest week in several years, closing above the consensus analyst price target. Shares settled at A$168.30 on Friday, August 21, following a 23.3% rise over five trading days. The surge boosted CSL’s market capitalisation by about A$14.5 billion.
The rerating came after results that clearly separated accounting losses from cash profit. CSL posted a statutory loss of US$2.58 billion, mostly due to US$7.1 billion in impairments. However, underlying NPATA was US$3.10 billion, while operating cash flow amounted to US$3.51 billion.
The adjustment was absorbed by investors ahead of analysts completing a full repricing. Latest data from 16 analysts reveals an average price target of A$163.62, which is 2.8% beneath Friday’s closing level. CSL has buy ratings from seven analysts, with nine advising to hold. No analysts have assigned a sell rating.
| Price checkpoint | Close | Daily move |
|---|---|---|
| Friday, Aug. 14 | A$136.50 | -0.7% |
| Results day, Aug. 18 | A$157.82 | +17.3% |
| Wednesday, Aug. 19 | A$166.48 | +5.5% |
| Thursday, Aug. 20 | A$171.20 | +2.8% |
| Friday, Aug. 21 | A$168.30 | -1.7% |
The week’s moves were more than a simple rebound. Tuesday’s 17.3% surge delivered the initial surprise, and momentum lasted through Thursday. Although the stock pulled back on Friday, it remained well above its lows and kept most of its gains, even as it finished under the A$175.94 weekly peak. Over the week, the S&P/ASX 200 slipped roughly 0.7%.
| FY2026 measure | FY2026 | Change at constant currency |
|---|---|---|
| Total revenue | US$15.80bn | down 1% |
| Underlying NPATA | US$3.10bn | down 2% |
| Underlying NPAT | US$2.84bn | down 3% |
| Operating cash flow | US$3.51bn | down 1% |
| Statutory NPAT | US$2.58bn loss | not comparable |
Interim Chief Executive Gordon Naylor described FY2026 as “a year of reset,” stating CSL had established “a clear path to return to sustainable growth.” The transformation has generated US$176 million in savings so far, ahead of schedule. Management is aiming for US$400 million in FY2027 and approximately US$550 million in FY2028.
The proposed A$1.1 billion buyback provides some backing, but it accounts for just a portion of the shift. This represents roughly 1.4% of CSL’s A$80.6 billion market capitalisation as of Friday. As a result, the gains rely more heavily on achieving earnings and cost objectives than on technical buying driven by the buyback.
| FY2027 guide | Management outlook | Investor read-through |
|---|---|---|
| Group revenue | Largely unchanged on a constant currency basis | Expansion opportunities limited |
| Underlying NPAT | Approximately +5% | Target at about US$2.98bn if realised |
| CSL Behring revenue | Mid-single-digit percentage increase | Plasma unit expected to drive results |
| CSL Seqirus revenue | Low-single-digit percentage increase | US vaccine market demand remains soft |
| CSL Vifor revenue | Approximately -25% | Headwind of around US$595m |
| Capital spending | US$1.0bn, with a range of plus or minus US$100m | Maintaining strong cash conversion is key |
CSL Behring continues to be central. Revenue for FY2026 decreased by 1% to US$11.39 billion. Immunoglobulin sales were unchanged for the full year, but gained 7% in the second half. ANDEMBRY entered 19 markets, and HEMGENIX revenue increased by 25%.
Vifor contributes the most significant impact. While its revenue increased by 3% in FY2026, CSL projects a drop of approximately 25% for this year. Increased competition in generic iron, the removal of TAVNEOS approval, and the cessation of VELPHORO’s reimbursement in the US all add to the strain. Based on basic calculations, this outlook points to an almost US$595 million reduction in revenue.
| Analyst view | Count or level | Versus A$168.30 close |
|---|---|---|
| Buy | 7 analysts | — |
| Hold | 9 analysts | — |
| Sell | 0 analysts | — |
| Average target | A$163.62 | -2.8% |
| Lowest target | A$132.08 | -21.5% |
| Highest target | A$205.57 | +22.1% |
The consensus table highlights the latest tension. CSL’s share price has moved ahead of the mean target, though the overall rating stays at Buy. New target adjustments could now have a greater impact than past earnings revisions.
Risks remain significant. Vifor’s drop may surpass projections, Chinese albumin prices might stay subdued, and weaker US vaccination uptake could impact Seqirus. CSL is also yet to appoint a permanent CEO. With shares up 23% in a week, expectations are now elevated and any disappointment would face tougher scrutiny.
| Next checkpoint | Date | Why it matters |
|---|---|---|
| ASX resumes trade | Monday, Aug. 24, about 10:00 AEST | First comprehensive trial since the weekly rerating |
| Final dividend ex-date | Wednesday, Sept. 9 | Stock trades ex-US$1.62 final dividend |
| Dividend record date | Thursday, Sept. 10 | Holders on this date become eligible |
| Dividend payout | Friday, Oct. 2 | US$1.62 per share is paid out |
The ASX remains shut throughout the weekend. Standard trading activity will restart around 10:00 AEST on Monday, and the closing auction will commence after 16:10 in Sydney. ASX cash-market hours The immediate question presented is straightforward: can earnings growth keep pace with valuations that have already surpassed expectations?
Related articles: ASX:CSL
![Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]](https://ts2.tech/wp-content/uploads/2026/08/AU-market-dashboard-2026-08-23-0843-480x384.jpg "Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]")
